Professor John McMurray joins us as a scientific advisor on our lead programme

We are honoured to welcome Professor John McMurray as a scientific advisor to River BioMedics on our lead programme, a small molecule, disease modifying approach to heart failure with preserved ejection fraction. Professor McMurray is currently Professor of Medical Cardiology and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.

Prof McMurray’s primary research interests are in heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, with a focus on clinical trials.  He is, or was, the principal investigator, member of the executive committee or steering committee member for several large trials in his areas of interest including the completed CHARM-Added, CORONA, I-Preserve, EMPHASIS-HF, PARADIGM-HF, ATMOSPHERE, Harmony-Outcomes, PARAGON-HF, GALACTIC-HF, DAPA-HF, DAPA-CKD, ASCEND-D and -ND trials, DELIVER, the ongoing FINEARTS-HF trial and the recently announced FINALITY trial.

He is a Past-President of the Heart Failure Association of the ESC and a Highly Cited Researcher with a H-index of >200.He was awarded an (honorary) OBE in 2019 by Her Majesty the Queen, in recognition of his services to cardiovascular research and in 2020 was awarded the Gold Medal of the European Society of Cardiology, which the society describes as “the highest honour it can bestow on exceptional scientists for their contribution to cardiovascular medicine”.